1st Rare and Genetic Neurodegenerative Drug Development Summit

Kongressthemen
Advance Life-Changing Therapies for Adolescents and Adults With Rare Neurological Disorders

Welcome to the 1st Rare and Genetic Neurodegenerative Drug Development Summit! This trailblazing meeting will be discussing, debating and exploring pivotal rare and genetic neurodegenerative disease research making industry news headlines.

Pioneers in this exclusive industry are convening online, this June, to network and learn from experts in pharma, biotech and academia.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Speakers: Anka G. Ehrhardt, Director, Cell-Based Assays / Analytical Research and Development, Merck, Christopher Missling, President and Chief, Executive Officer, Anavex Life Sciences, David Theron, Development Director in Neurology, Servier & more

https://go.evvnt.com/1056250-2?pid=4832

Herr Hanson Wade